Showing 4511-4520 of 4942 results for "".
- Skin Cancer Foundation: Dermatologists and Beauty Professionals Team Up to Spot Skin Cancershttps://practicaldermatology.com/news/20141113-skin_cancer_foundation_dermatologists_and_beauty_professionals_team_up_to_spot_skin_cancers/2459069/The Skin Cancer Foundation is encouraging dermatologists and beauty professionals to work together through an education program called Heads Up! The skin cancer awareness program provides beauty professionals, including hair stylists and aestheticians, with tips on what to look for, and how to speak
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Study Finds that the Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanomahttps://practicaldermatology.com/news/20141024-study_finds_that_the_use_of_melafind_reduced_benign_biopsies_by_61_in_patients_at_risk_for_melanoma/2459079/The study, conducted independently and not sponsored by MELA Sciences, Inc. had an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. 64 of those lesions were identified for biopsy and 102 were selected for continued observati
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- Researchers to Present Gigapixel Whole-Body Camera at OSA Annual Meetinghttps://practicaldermatology.com/news/20141008-researchers_to_present_gigapixel_whole-body_camera_at_osa_annual_meeting/2459091/A new “gigapixel whole-body photographic camera” may provide an option for tracking changes in potentially cancer skin lesions. Duke University researchers who developed the imaging technology will presenting it at the The Optical Society's (OSA) 98th Annual Meeting, Frontiers in Optics, Oct. 19-23
- Peter Barton Hutt Appointed to Suneva Medical, Inc. Board Of Directorshttps://practicaldermatology.com/news/20141008-peter_barton_hutt_appointed_to_suneva_medical_inc_board_of_directors/2459093/Peter Barton Hutt was appointed a member of the Board of Directors of Suneva Medical, Inc., a privately-held aesthetics company. Mr. Hutt has specialized in food and drug law at the Washington, DC firm of Covington and Burling since 1960, pausing only to serve as Chief Counsel o
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre
- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Teledermatology App Teams Up with Dermatologistshttps://practicaldermatology.com/news/20141002-teledermatology_company_teams_up_with_dermatologists/2459098/A new teledermatology app is partnering with board- and state-certified dermatologists to assist patients with on-the-spot information regarding the detection and evaluation of skin disease in early stages. Having launched already in 13 states, Klara has partnered up with Dr. Mark Kaufmann, MD, Asso